doc. dr. sc. Dragan Trivanović

Current Appointments

General Hospital Pula

Vice Chair Hospital, Quality Management and Head of Department of 

Oncology and Hematology

Negri 6, 52100 Pula, Croatia

October 2016-present

University of Pula

Postgraduate Nursing Study of Biomedicine and Health

Assist.profess. and Research Associate

Zagrebačka 30, 52100 Pula, Croatia

June 2016-present

University of Rijeka

 Medical School Rijeka


Department of Internal Medicine

B.Branchetta 20, 51000 Rijeka, Croatia

December 2015-present            



2009 – 2010   Subspecialisation

Medical Oncology Clinical Hospital Rijeka,

Krešimirova 421, 51000 Rijeka, Croati

2003 – 2009    PhD Doctor of Philosophy

University of Rijeka, Medical School

Trg braće Mažuranića 10, 51000 Rijeka, Croatia

2003 – 2007   Resident Internal Medicine

Clinical Hospital Rijeka,

Krešimirova 42, 51000 Rijeka, Croatia

1999 – 2003    Msc Master of Science

University of Rijeka, Medical School

Trg braće Mažuranića 10, 51000 Rijeka, Croatia

1987 – 1993  MD Doctor of Medicine

University of Zagreb, Medical School,

Šalata 3, 10000 Zagreb, Croatia



2017    The Royal College of Physicians 

Oncology at the limits, Lancet Oncology Educational Program

11 St Andrews Place, Regent’s Park

London NW1 4LE, United Kingdom

2011  Cicely Saunders Institute,

Palliative Care Education

Bessemer Road,

London SE5 9PJ, United Kingdom

2009  St. Christopher Hospice, London

Palliative Care Education

51-59 Lawrie Park Road, Sydenham

London, SE26 6DZ, United Kingdom

2006  Weil-Cornell by Memorial Sloan Kettering Cancer Center

 Hematology education

  Salzburg, Austria

2005     Cleveland Clinical Hospital Observership

Taussig Cancer Centre, Hematology Department

Mentored by Alan Lichtin

10524 Euclid Ave. Cleveland, OH 44195


Professional Experience

2016-present     Vice Chair Hospital, Quality Management

General Hospital Pula

Negri 6, 52100 Pula, Croatia

2012-present     Head of Department of Oncology and Hematology

General Hospital Pula

Negri 6, 52100 Pula, Croatia

2013-2016        Head of Department of Internal Medicine

General Hospital Pula

Negri 6, 52100 Pula, Croatia

2012-2013        Hospital Board Member

General Hospital Pula

Negri 6, 52100 Pula, Croatia

2007-2012        Internist, Oncologist

General Hospital Pula

 Department of Internal Medicine

Negri 6, 52100 Pula, Croatia

2005-2007        Resident Internal Medicine

Clinical Hospital Rijeka

Krešimirova 42, 51000 Rijeka, Croatia

2003-2005        Resident Internal Medicine

General Hospital Pula

Department of Internal Medicine

Negri 6, 52100 Pula, Croatia

2000-2003        Doctor of Medicine

General Hospital Pula

  Department of Internal Medicine

Negri 6, 52100 Pula, Croatia

1997-2003        Doctor of Medicine

Surgical Policlinic St Pellegrin

 Stella Maris, 52470, Umag, Croatia


Licensure & Certification

Croatian Medical Chamber

Board Certification 2015-present

Licence No. 10434

Association of Clinical Research Certification

GCP certificate 2018 -present


Awards and Honors

2018     Adris Foundation award

2016     Croatian Cancer League, Istria Award 50 years


Professional Associations

2009-present     American Society of Medical Oncology

Full Member ID 87601

2017-present     Croatian Society for Quality Improvement in Health Care

2009-present     Croatian Association of Clinical Oncology

2000-present     Croatian Medical Chamber and Croatian Medical Association



Current non-profit studies

2018-present     Patient reported outcomes project

2016-present     Pepsinogen in Early Detection of Gastric Cancer

(EudraCT number 2016-000519-34 has been issued for your Sponsor’s Protocol Code Number 1068).

2016-present     Erectile Dysfunction in Patients with Prostate Cancer

2015-present     Web page:


Editorial Boards

2009-present     Glasnik Pulske Bolnice (Journal of General Hospital Pula)




Herceg D, Jakopović M, Trivanovic D et al. Cancer patients follow-up    croatian society for medical oncology clinical guidelines part v: melanoma,       sarcomas, central nerve system tumors, lung cancer. Lijec Vjesn      2017;139:17–23.               Šeparović R, Silovski T, Trivanović D et al. Cancer patients follow-up               croatian society of medical oncology clinical guidelines part i: breast cancer,                uterine cancer, cervical cancer, ovarian cancer. Lijec Vjesn 2016;138:63–68.               Bišof V, Juretić A, Trivanović D et al. Clinical recommendations for                 diagnosis, treatment and monitoring of patients with cancer of unknown                 primary site. Lijec Vjesn. 2015;137:65-9.     Dobrila-Dintinjana R, Trivanovic D, Zelic M, Radic M, Dintinjana M,                      Petranovic D, Toni V, Vukelic J, Matijasic N. Nutritional Support in   Patients with Colorectal Cancer during Chemotherapy: Does it Work?               Hepatogastroenterology. 2013;60:475-80.    Trivanović D, Petković M, Štimac D. New Prognostic Index to Predict   Survival in Patients with Cancer of Unknown Primary Site with               Unfavourable Prognosis Clinical Oncology. 2009;21:43-48.    Trivanović D, Petković M, Štimac D. Low serum albumin levels and liver      metastasis are powerful prognostic markers for survival in patients with      carcinomas of unknown primary site. Cancer. 2007;109:2623-4.Publications as contributor in Clinical trials   Paz-Ares L, Mezger J, Ciuleanu TE et al. INSPIRE investigators          (Trivanovic D.). Necitumumab plus pemetrexed and cisplatin as first-line     therapy in patients with stage IV non-squamous non-small-cell lung cancer      (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet     Oncol. 2015;16:328-37.               Fuchs CS et al. (Trivanovic D.) Ramucirumab monotherapy for previously                  treated advanced gastric or gastro-oesophageal junction adenocarcinoma                (REGARD): an international, randomised, multicentre, placebo-controlled,                 phase 3 trial. Lancet. 2014;383:31-9. (contr.)   Lang I, Brodowicz T, Ryvo L et al.Central European Cooperative Oncology    Group Investigators (Trivanovic D.). Bevacizumab plus paclitaxel versus    bevacizumab plus capecitabine as first-line treatment for HER2-negative    metastatic breast cancer: interim efficacy results of the randomised, open-   label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol.       2013;14:125-33.(contr.)               Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P,                Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators                (Trivanovic D.). Semuloparin for thromboprophylaxis in patients receiving                chemotherapy for cancer. N Engl J Med. 2012;366:601-9.


Abstracts (selected international)

Trivanovic D, Hrstic I, Budisavljevic A et al.  Patient related outcomes in cancer patients in Croatia. J Clin Oncol 37, 2019 (suppl; abstr TPS6650)

Trivanovic D, Plestina S. Honovic L et al. Final results of early non-invasive gastric         cancer detection study using the serum pepsinogen test method in Croatian patients.           J Clin Oncol 37, 2019 (suppl; abstr e15551)

  1.   Trivanovic, L. Honovic, J. Vlasic, I. Hrstic. Early non-invasive

    detection of gastric cancer with plasma pepsinogens in Croatian patients.

    ESMO Annual Congress Kopenhagen, 2016.

    Trivanovic D,  Kocic L,  Dembic M,  Spasic N,  Budisavljevic A. Prognostic      Factors Associated with Overall Survival in Croatian Patients with Advanced Lung      Cancer 16th World Conference on Lung Cancer,     Denver, Colorado, USA 2015.    Vrdoljak E, Soldic Z, Gasparic M, Boskovic L, Belac Lovasic I, Dabelic N,           Gugic D,  Ledina D,  Bozic Sakic M, Raspovic Z, Zorica R, Trivanovic D,             Petkovic M Optimization of breast cancer patients’ follow-up – potential               way to improve cancer care in transition countries. ESMO Annual Congress       Vienna 2015.

Trivanovic D, Spasic N, Plestina S, Dobrila-Dintinjana R, Kocic L. Impact of complementary and alternative medicine (CAM), religiosity, and  evidence-based medicine (EBM) in advanced cancer patients. Clin Oncol

 32, 2014 (suppl; abstr e12000) ASCO Annual Congress, Chicago, IL 2014.

Trivanovic D, Spasić N, Pleština S et al. Chemobrain in patients   

participating in clinical trials. ESMO Annual Congress 2013.Amsterdam.

Trivanovic D, Plestina S, Dobrila-Dintinjana R, Honovic L, Jerin L, Hrstic I.         Vitamin D3 supplementation to improve fatigue in patients with advanced cancer.J Clin Oncol 30, 2012 (suppl; abstr 9097). Chicago ASCO 2012.               Trivanovic D., Plestina S., Jerin L., Honovic L.  An open-label randomized                phase II trial of oral vitamin D3 supplementation in combination with                standard chemotherapy or best supportive care compared with standard                chemotherapy and best supportive care in patients with advanced solid                tumors. J Clin Oncol 29: 2011 (suppl; abstr e19566). Chicago ASCO 2011.

 Trivanović D, Petković M, Dobrila Dintinjana R, Mavrić Ž, Štimac D. QTc interval in advanced cancer patients. J Clin Oncol;27: 2009. (suppl;abstr e20658). Orlando ASCO 2009.

Trivanović D. Interactive case report. Reply to Sodeck et al. BMJ 326 : 974  doi: 10.1136/bmj.326.7396.974 (Published online 3 May 2003).


Book Chapters


Beslija, Vrbanec et al. Medical Oncology, 2nd edition 2019. In press.

Balenović A et al. Trivanović D. Kliničke Onkološke Studije u PET/CT Klinička primjena. Hazu Zagreb 2015.

Trivanović D. Dobrila Dintinjana R. Onkološki pristup tumorima jetre   hepatobilijarnih puteva. Medix, Zagreb 2013.

Dobrila-Dintinjana R, Trivanović D et al. Effects of Dietary Counseling on    

Patients with Colorectal Cancer. Colorectal cancer in book:  From prevention

To patient care Edited by Rajunor Ettarh. Intech 2012.



Trivanovic D. Diagnostic and Prognostic Factors in Patients with Cancer of  

Unknown Primary Site. University of Rijeka: Rijeka, Croatia 2009. (PhD 



Invited Talks/presentations

              Trivanovic D. Clinical Importance of Tumor Heterogeneity. HLZ, Pula 2017.

  Trivanovic D, Bermanec S, Brumini D. Analiza smrtnosti palijativnih bolesnika u  

  OB Pula i ŽB Čakovec. 2.Kongres palijativne skrbi Pula 2016

              Trivanovic D. Tumor Heterogeneity. 3.kongres hrvatskog društva za 

  internističku onkologiju HLZ-a. Zagreb 2015.

Trivanović D. Patient with metastatic gastroesophageal junction cancer    

  (durable response on 2nd line therapy with ramucirumab). 5.HDIO Zagreb 2013.

Trivanović D. Chemotherapy of Liver Tumours. 1st IASGO CME Croatia 

  course Rovinj 2013.


Clinicial trials:




Year 2008.
Study A Multinational, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and who are Undergoing ChemotherapyProtocol Number: EFC6521 – SAVE-ONCO
  Principal Investigator



Year 2009.
Study A multinational, Randomized, Double-blind Study Comparing the Efficacy and Safety of Aflibercept versus Placebo Administered every 3 weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate CancerProtocol Number: EFC6546-VENICE
  Principal Investigator


Year 2010.
Study A Randomized, Multi-Center, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus IMC-11F8 Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Squamous Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Protocol Number: IMCL CP11-0806
  Principal Investigator



Year 2010.
Study A Randomized, Multi-Center, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus IMC-11F8 Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Nonsquamous Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Protocol Number: IMCL CP11-0805
  Principal Investigator


Year 2010.
Study A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancerProtocol Number: BO22280 Tryphaena
  Principal Investigator




Year 2011.
Study A Randomized, Phase IIb/III Study Of Ganetespib (Sta-9090) in Combination with Docetaxel versus Docetaxel Alone in Subjects With Stage Iiib or IvNon-Small-Cell Lung Cancer Protocol Number: 9090-08
  Principal Investigator


Year 2011.
Study A Phase 3, Randomized, Double-Blinded Study of IMC-1121B andBest Supportive Care (BSC) Versus Placebo and BSC in the Treatmentof Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaFollowing Disease Progression on First-Line Platinum- orFluoropyrimidine-Containing Combination Therapy Protocol Number: IMCL CP12-0715 REGARD
  Principal Investigator


Year 2011.
Study A Phase 3, Multicenter, Randomized, Open Label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With ChemorefractoryWild-Type KRAS Metastatic Colorectal Cancer Protocol Number: AMGEN 20100007
  Principal Investigator


Year 2012.
Study Multiple, Fixed-Dose, Comparative Efficacy and Safety Evaluation Of Rgb-02 and Neulasta® In Patients Undergoing Chemotherapy Treatment Known to Induce NeutropeniaProtocol Number: RGB-02-101
  Principal Investigator



Year 2012.
Study A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer Protocol Number: CECOG/BC 1.3.005
  Principal Investigator


Year 2012.
Study Phase Iii, Randomized, Double Blind, Placebo-Controlled Study of Vemurafenib(Ro5185426) Adjuvant Therapy In Patients with Surgically Resected, Cutaneous Braf-Mutant Melanoma At High Risk For RecurrenceProtocol Number GO27826
  Principal Investigator




Year 2013.
Study A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMab) in Combination with Tarceva ® (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Lung Cancer (NSCLC) who have Received Standard Chemotherapy forAdvanced or Metastatic Disease Protocol Number: OAM4971g
  Principal Investigator





Year 2014.
Study A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel alone in Patients with Advanced Non- Small-Cell Lung AdenocarcinomaProtocol Number:  9090-14
  Principal Investigator


Year 2014.
Study A Phase 3 Randomized, Double-Blind Study of Pf-06439535 PlusPaclitaxel-Carboplatin and Bevacizumab Plus Paclitaxel-Carboplatin For The First-Line Treatment of Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Protocol Number:  B7391003
  Principal Investigator




Year 2014,
Study Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin andPaclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Protocol Number: M11-089
  Principal Investigator


Year 2016.
Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study ofPEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Protocol Number: HALO 109-301
  Glavni ispitivač


Year 2017.
Study A multicenter, randomized, double-blind Phase III trial to evaluateefficacy and safety of BI 695502 plus chemotherapy versus Avastin®plus chemotherapy in patients with advanced nonsquamous Non-SmallCell Lung CancerProtocol Number: BI695502
  Principal Investigator




Current clinical trials


YearStudy 2019,A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)Protocol Number: ANAM 17-21
  Principal Investigator
YearStudy 2019,ALRN-6924-1-03, Protocol A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Topotecan-induced Myelosuppression During Treatment forSmall Cell Lung Cancer,Protocol Number: ALRN-6924-1-03
  Principal Investigator
YearStudy 2019,A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)Protocol Number: Brigatinib – 30001.
  Principal Investigator
YearStudy 2019,A Real World Evidence Prospective Cohort Study in the Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective(PROMETCO)Protocol Number: PROMETCO
  Principal Investigator
YearStudy Phase 2 Study of PD-1 lnhibitor iTX-4014 Alone and in Combination withVopratelimab, an ICOS Agonist, in Biomarker-selected Subjects with Metastatic NSCLC After One Prior Platinum-containing RegimenProtocol Number: JTX-40L4-202 SELECT
  Principal Investigator